An introduction into NK cell cancer immunotherapy – Pharmaceuticals

By Easha Vigneswaran Cancer, one of the most difficult diseases to treat, is at the forefront of the pharmaceutical world for the development of treatments. From drugs to monoclonal antibodies, all forms of therapy are being tested with many having vast amounts of success. However, inevitably, there are also many cancers that are becoming increasinglyContinue reading An introduction into NK cell cancer immunotherapy – Pharmaceuticals”

An introduction to HIV treatments

By Allis Lai Human immunodeficiency virus, or HIV, is one of the leading causes of morbidity and mortality across the globe. The retrovirus attacks the immune system, leading to loss of functional T cells and causing an increased risk of infections, bone disease, kidney and liver dysfunction, and other complications. The virus is transmitted viaContinue reading An introduction to HIV treatments

Are COVID jabs the best way to protect children?

By Jasper Kan Since it’s first recorded outbreak in China, SARS-CoV-2 (COVID-19) has wreaked havoc among humanity, bringing numerous casualties and the world to a standstill. While many (including governments) believe indiscriminate vaccination is the only way out, others doubt the unknown effects that a novel vaccine exerts. This doubt is particularly concerning for theContinue reading “Are COVID jabs the best way to protect children?”

siRNAs: the future of cholesterol management?

By Allis Lai On September 1, 2021, NICE approved inclisiran, a new siRNA drug for patients with primary hypercholesterolaemia or mixed dyslipidaemia.1 This is a big step forward for RNA therapeutics, a field that has been rapidly gaining traction in the past two decades. Small interfering RNA, known in short as siRNA, is a shortContinue reading siRNAs: the future of cholesterol management?

Cucurbitacin – a poison or a medicine?

By Fiona Zhang Ever wondered why cucumbers and zucchinis can have a bitter taste? Try slicing off both ends of a cucumber and rubbing the flesh-exposed face of one sliced end with that of the cucumber. Soon you will extract a white foamy substance. Eat the cucumber after this, and the cucumber will no longerContinue reading “Cucurbitacin – a poison or a medicine?”

Computational Approaches for Drug Repurposing

By Thomas Philpott Due to the slow pace and substantial costs of new drug discovery and development, drug repurposing has become an attractive alternative.1 Drug repurposing is a strategy for identifying new uses for existing drugs, including approved, discontinued and investigational therapeutics.2 The COVID-19 pandemic has led to an urgency for developing new drugs toContinue reading Computational Approaches for Drug Repurposing

The potential of Topoisomerase II as an anticancer drug target

By Yawen (Angela) Yang Topoisomerase II (TOP2) is an enzyme engaged in DNA replication, transcription and chromosomal segregation.1 During DNA replication and transcription, DNA helicase separates double-stranded DNA into single strands. However, helicase cannot unwind DNA indefinitely because DNA ahead of the replication fork becomes overwound and forms supercoils. The tension built up makes DNAContinue reading “The potential of Topoisomerase II as an anticancer drug target”

Idiosyncratic drug-induced liver injury

By Jessica Lu Drug-induced liver injury (DILI) is the most common cause of acute liver failure in Europe and in the USA.1 For some drugs such as acetaminophen, DILI is dose-dependent, predictable, and reproducible in preclinical models. However, DILI onset may also be idiosyncratic – characterised by a variable latency to onset (weeks to months)Continue reading Idiosyncratic drug-induced liver injury

A next-generation vaccine platform—self-amplifying mRNA(saRNA)

By Victoria Zhang The world has witnessed a shift towards using synthetic RNA platforms for vaccine development during the COVID-19 pandemic, where non-replicating mRNA vaccines play a crucial role.1 But non-replicating mRNA vaccines are not the only type of RNA molecules used in the RNA vaccine family, the other two types being base-modified non-amplifying mRNA(bmRNA)Continue reading A next-generation vaccine platform—self-amplifying mRNA(saRNA)

COVID Oral Antivirals: The next chapter in COVID Therapeutics 

By Souheil-Eddine Zitouni  Over the past couple of months, two oral antiviral drugs have been branded to reduce COVID-19 deaths and admission into hospital after clinical studies of patients treated readily after initial infection. If these trends are replicated in a real-life setting, these antivirals could forge the next chapters of what has seemed toContinue reading COVID Oral Antivirals: The next chapter in COVID Therapeutics